A5010525723- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- Immune cells in cancer
- Long-Term Effects of COVID-19
- Viral gastroenteritis research and epidemiology
- RNA Interference and Gene Delivery
- Immune Response and Inflammation
- vaccines and immunoinformatics approaches
- CRISPR and Genetic Engineering
- Phagocytosis and Immune Regulation
- Virus-based gene therapy research
- Nanoplatforms for cancer theranostics
- Innovation and Socioeconomic Development
- Vaccine Coverage and Hesitancy
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- COVID-19 Impact on Reproduction
- Cancer-related molecular mechanisms research
- interferon and immune responses
- Epigenetics and DNA Methylation
- Sarcoma Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- Cancer Cells and Metastasis
- Inflammasome and immune disorders
Sichuan University
2019-2025
State Key Laboratory of Biotherapy
2019-2024
National Clinical Research
2023
Shanghai Medical Information Center
2022
Jiangsu Agri-animal Husbandry Vocational College
2017
Abstract Coronavirus disease 2019 (COVID‐19) has brought about a great threat to global public health. Recently, new severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variant B.1.1.529 been reported in South Africa and induced rapid increase COVID‐19 cases. On November 24, 2021, named Omicron was designated as under monitoring (VUM) by World Health Organization (WHO). Two days later, the classified of concern (VOC). This harbors high number mutations, including 15 mutations...
As the fifth variant of concern SARS-CoV-2 virus, Omicron (B.1.1.529) has quickly become dominant type among previous circulating variants worldwide. During wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two subvariants, BQ.1 XBB lineages, including BQ.1.1, XBB.1, XBB.1.5, a global public health issue given ability to escape from therapeutic monoclonal antibodies herd...
Abstract The recently emerged Omicron (B.1.1.529) variant has rapidly surpassed Delta to become the predominant circulating SARS-CoV-2 variant, given higher transmissibility rate and immune escape ability, resulting in breakthrough infections vaccinated individuals. A new generation of vaccines targeting are urgently needed. Here, we developed a subunit vaccine named RBD-HR/trimer by directly linking sequence RBD derived from (containing L452R T478K) HR1 HR2 S2 tandem manner, which can...
Abstract The COVID-19 response strategies in Chinese mainland were recently adjusted due to the reduced pathogenicity and enhanced infectivity of Omicron subvariants. In Chengdu, China, an infection wave was predominantly induced by BA.5 subvariant. It is crucial determine whether hybrid anti-SARS-CoV-2 immunity following infection, coupled with a variety immune background, sufficient shape responses against newly emerged subvariants, especially for XBB lineages. To investigate this, we...
Abstract The tumor-associated macrophage (TAM) is the most abundant group of immune cells in tumor microenvironment (TME), which plays a critical role regulation progression and treatment resistance. Based on different polarization status, TAMs may also induce antitumor responses or immunosuppression. present study identified JMJD6 (Jumonji domain-containing 6) as novel modulator TAM activation, upregulation was associated with immunosuppressive activities TAMs. deficiency attenuated growth...
Background Mitochondrial transcription factor A (TFAM) is a that maintains mitochondrial DNA (mtDNA) stabilization and initiates mtDNA replication. However, little known about the immune regulation function TFAM expression in cells tumors. Methods Mouse tumor models were applied to analyze effect of deficiency myeloid cell lineage on progression microenvironment (TME) modification. In vitro, primary mouse bone marrow-derived dendritic (BMDCs) used investigation altered activated pathway. OVA...
Abstract Somatostatin receptor 2 (SSTR2) is highly expressed in neuroendocrine tumors and represents as a therapeutic target. Several peptide analogs mimicking the endogenous ligand somatostatin are available for clinical use, but poor effects occur subset of patients, which may be correlated with subtype selectivity or cell surface expression. Here, we clarify signal bias profiles first-generation drug octreotide new-generation small molecule paltusotine by evaluating their pharmacological...
Abstract Mucosal immunity plays a significant role in the first-line defense against viruses transmitted and infected through respiratory system, such as SARS-CoV-2. However, lack of effective safe adjuvants currently limits development COVID-19 mucosal vaccines. In current study, we prepare an intranasal vaccine containing cationic crosslinked carbon dots (CCD) SARS-CoV-2 antigen, RBD-HR with spontaneous antigen particlization. Intranasal immunization CCD/RBD-HR induces high levels...
Abstract The emergence of XBB- and JN.1-lineages with remarkable immune evasion characteristics have led to rises in breakthrough infections within populations. In addition, the unfavorable impacts imprinting, stemming from continuous exposure antigens circulated viruses, been observed incline response against earlier lineages, thereby declining neutralization newly emerged Omicron subvariants. this, advancement next-generation vaccines COVID-19 targeting components new subvariants such as...
Abstract Despite the declared end of COVID-19 pandemic, SARS-CoV-2 continues to evolve, with emerging JN.1-derived subvariants (e.g., KP.2, KP.3) compromising efficacy current XBB.1.5-based vaccines. To address this, we developed an mRNA vaccine encoding full-length spike protein JN.1, incorporating GSAS and 2P mutations encapsulated in lipid nanoparticles (LNPs). The JN.1-mRNA elicited robust humoral cellular immune responses mice, including high JN.1-specific IgG titers, cross-neutralizing...
ABSTRACT Respiratory syncytial virus (RSV) causes severe acute lower respiratory tract infections, especially in infants and the elderly. Developing an RSV vaccine that promotes a robust mucosal immune response is necessary to successfully prevent viral transmission development of disease. We previously reported crosslinked carbon dots (CCD) may be excellent adjuvant candidate for intranasal (IN) protein subunit vaccines. Considering strong immunogenicity prefused F (preF), we prepared IN...
Several SARS-CoV-2 variants have emerged since the pandemic, bringing about a renewed threat to public. Delta variant (B.1.617.2) was first detected in October 2020 India and characterized as of concern (VOC) by WHO on May 11, 2021. rapidly outcompeted other become dominant circulating lineages due its clear competitive advantage. There is emerging evidence enhanced transmissibility reduced vaccine effectiveness (VE) against variant. Therefore, it crucial understand features phenotypic...
The emerging variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in pandemic call for the urgent development universal corona virus disease 2019 (COVID-19) vaccines which could be effective both wild-type SARS-CoV-2 and mutant strains. In current study, we formulated protein subunit with AS03 adjuvant recombinant proteins S1 (S1-WT) variant (K417N, E484K, N501Y, D614G) (S1-Mut), immunized transgenic mice that express human angiotensin-converting enzyme 2 (hACE2)....
Abstract Neutrophil extracellular traps (NETs) can capture and kill viruses, such as influenza human immunodeficiency virus (HIV), respiratory syncytial (RSV), thus contributing to host defense. Contrary our expectation, we show here that the histones released by NETosis enhance infectivity of SARS-CoV-2, found using live SARS-CoV-2 two pseudovirus systems well a mouse model. The histone H3 or H4 selectively binds subunit 2 spike (S) protein, shown biochemical binding assay, surface plasmon...
The XBB.1.5 subvariant has drawn great attention owing to its exceptionality in immune evasion and transmissibility. Therefore, it is essential develop a universally protective coronavirus disease 2019 vaccine against various strains of Omicron, especially XBB.1.5. In this study, we evaluated compared the responses induced by six different spike protein vaccines targeting ancestral or Omicron severe acute respiratory syndrome 2 (SARS-CoV-2) mice. We found that spike-wild-type immunization...